Biström Martin, Alonso-Magdalena Lucia, Andersen Oluf, Jons Daniel, Gunnarsson Martin, Vrethem Magnus, Hultdin Johan, Sundström Peter
Department of Pharmacology and Clinical Neuroscience, Umeå University, Sweden.
Department of Neurology, Skåne University Hospital in Malmö/Lund and Institution of Clinical Sciences, Neurology, Lund University, Sweden.
Mult Scler J Exp Transl Clin. 2019 Dec 6;5(4):2055217319892291. doi: 10.1177/2055217319892291. eCollection 2019 Oct-Dec.
High 25-hydroxyvitamin D concentrations have been associated with a reduced risk of multiple sclerosis, with indications of a stronger effect among young individuals.
Investigate the 25-hydroxyvitamin D association with multiple sclerosis and test if this association is age dependent.
Prospectively drawn blood samples from individuals later developing relapsing-remitting multiple sclerosis and controls matched for biobank, sex, age and date of sampling, were analysed with liquid chromatography tandem mass spectrometry.
High levels of 25-hydroxyvitamin D (top quintile) were associated with a reduced multiple sclerosis risk (odds ratio 0.68, 95% confidence interval 0.50-0.93).
These findings further support a role for vitamin D in MS aetiology.
25-羟基维生素D浓度较高与多发性硬化症风险降低有关，且有迹象表明在年轻人中这种作用更强。
研究25-羟基维生素D与多发性硬化症的关联，并检验这种关联是否与年龄有关。
采用液相色谱串联质谱法分析前瞻性采集的血液样本，这些样本来自后来发展为复发缓解型多发性硬化症的个体以及与生物样本库、性别、年龄和采样日期相匹配的对照组。
25-羟基维生素D水平较高（最高五分位数）与多发性硬化症风险降低相关（比值比0.68，95%置信区间0.50 - 0.93）。
这些发现进一步支持了维生素D在多发性硬化症病因学中的作用。
